JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

IQVIA Holdings Inc

Aperta

SettoreSettore sanitario

219.72 0.64

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

214.29

Massimo

222.03

Metriche Chiave

By Trading Economics

Entrata

17M

266M

Vendite

188M

4B

P/E

Media del settore

29.657

37.461

Margine di Profitto

6.622

Dipendenti

90,000

EBITDA

28M

781M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+6.32% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

8.5B

36B

Apertura precedente

219.08

Chiusura precedente

219.72

Notizie sul Sentiment di mercato

By Acuity

34%

66%

97 / 373 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

IQVIA Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 ott 2025, 23:50 UTC

Azioni calde

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 ott 2025, 23:25 UTC

Utili

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 ott 2025, 23:18 UTC

Utili

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 ott 2025, 22:20 UTC

Utili

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 ott 2025, 22:13 UTC

Utili

Wal-Mart de Mexico Net Profit Falls in 3Q

28 ott 2025, 21:38 UTC

Utili

Correction to Visa Sales Jump Article

28 ott 2025, 21:17 UTC

Utili

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 ott 2025, 21:07 UTC

Utili

Visa Sales Jump as Consumers Keep Spending -- Update

28 ott 2025, 21:02 UTC

Utili

Mondelez Tempers Outlook as Costs Rise

28 ott 2025, 23:51 UTC

Discorsi di Mercato

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 ott 2025, 23:42 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 ott 2025, 23:02 UTC

Utili

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 ott 2025, 23:01 UTC

Utili

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 ott 2025, 22:46 UTC

Utili

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 ott 2025, 22:45 UTC

Utili

SK Hynix 3Q Net KRW12.6T >000660.SE

28 ott 2025, 22:44 UTC

Utili

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 ott 2025, 22:43 UTC

Utili

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 ott 2025, 22:42 UTC

Utili

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 ott 2025, 22:40 UTC

Utili

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 ott 2025, 22:40 UTC

Utili

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 ott 2025, 22:20 UTC

Utili

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 ott 2025, 22:02 UTC

Utili

Review & Preview: Earnings Extravaganza -- Barrons.com

28 ott 2025, 21:42 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

28 ott 2025, 21:42 UTC

Discorsi di Mercato
Utili

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 ott 2025, 21:20 UTC

Utili

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 ott 2025, 21:19 UTC

Utili

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 ott 2025, 21:18 UTC

Utili

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Confronto tra pari

Modifica del prezzo

IQVIA Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

6.32% in crescita

Previsioni per 12 mesi

Media 231.91 USD  6.32%

Alto 258 USD

Basso 200 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per IQVIA Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

12

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

150.68 / 153.45Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Neutral Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

97 / 373 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat